|
Alopecia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Analysis of the QLQ-C15-PAL and BN20 scales revealed significant deterioration in patients treated with WBRT and SRT in physical function (p < 0.001 and p = 0.007), fatigue (p < 0.001 and p = 0.036), nausea (p = 0.003 and p = 0.002), appetite loss (p < 0.001 and p = 0.025), drowsiness (p < 0.001 and p = 0.011), hair loss (p = 0.019 and p = 0.023) and itchy skin (p = 0.030 and p = 0.018).
|
31418046 |
2020 |
|
Ankylosing spondylitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
VEGFR-2 expressing stromal blood vessels, also positive for the vascular endothelial marker PAL-E and the basement membrane marker laminin, were more abundant in RA and AS than in controls.
|
11824969 |
2002 |
|
Anorexia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Analysis of the QLQ-C15-PAL and BN20 scales revealed significant deterioration in patients treated with WBRT and SRT in physical function (p < 0.001 and p = 0.007), fatigue (p < 0.001 and p = 0.036), nausea (p = 0.003 and p = 0.002), appetite loss (p < 0.001 and p = 0.025), drowsiness (p < 0.001 and p = 0.011), hair loss (p = 0.019 and p = 0.023) and itchy skin (p = 0.030 and p = 0.018).
|
31418046 |
2020 |
|
Bodily Pain
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Convergent validity was demonstrated with PAL-I total score and Roland-Morris Disability Questionnaire (Pearson correlation 0.82), MOS-36 Physical Functioning (-0.71), and MOS-36 Bodily Pain (-0.71).
|
29889120 |
2018 |
|
Caffeine related disorders
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The comparison of TGY vs. BS revealed eight up-regulated genes (PAL, C4H, CHS, F3'H, F3H, DFR, ANS, and ANR) and two down-regulated genes (FLS and CCR) in flavonoid metabolism, four up-regulated genes (AMPD, IMPDH, SAMS, and 5'-Nase) and one down-regulated XDH gene in caffeine metabolism; and two down-regulated genes (ALDH and HIBADH) in limonene degradation.
|
30943892 |
2019 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We also discuss the possible involvement of the PAL-mechanism in carcinogenesis.
|
15970690 |
2005 |
|
Cerebrovascular accident
|
0.010 |
Biomarker
|
group |
BEFREE |
Thirty people with stroke (mean ± standard deviation, age: 63.8 ± 12.3 years, time since stroke: 3.6 ± 1.1 months) wore an activPAL3 Micro accelerometer (PAL Technologies, Glasgow, Scotland) continuously for 7 days to measure whole-day activity behavior.
|
28669653 |
2017 |
|
Chronic low back pain
|
0.010 |
Biomarker
|
disease |
BEFREE |
The PAL-S has demonstrated content validity and is potentially useful to assess treatment benefit in cLBP clinical trials.
|
29432327 |
2018 |
|
Classical phenylketonuria
|
0.010 |
Biomarker
|
disease |
BEFREE |
Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study.
|
29973227 |
2018 |
|
cocaine use
|
0.010 |
Biomarker
|
disease |
BEFREE |
3-Fluoroamphetamine (also called PAL-353) is a synthetic amphetamine analog that has been investigated for cocaine use disorder (CUD), yet no studies have characterized its pharmacokinetics (PK).
|
31642004 |
2020 |
|
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A lectin with strong cytotoxic effect on human colon cancer HT29 and monkey kidney VERO cells was recently identified from the Australian indigenous mushroom Psathyrella asperospora and named PAL.
|
28168856 |
2017 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We retrospectively compared 33 consecutive cases treated with 18-mm-diameter stents (bridge to surgery [BTS] in 25, palliative therapy [PAL] in 8) with 27 consecutive cases treated with 22-mm-diameter stents (BTS in 21, PAL in 6) for obstructive colorectal cancer between May 2013 and November 2015 in our institution.
|
29258112 |
2017 |
|
Congestive heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
(Palliative Care in Heart Failure [PAL-HF]; NCT01589601).
|
28705314 |
2017 |
|
Depressed mood
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
NEIS, HADS and EORTC QLQ-C15-PAL were assessed at baseline (T0), 1 month later (post-treatment; T1), and at 1 month follow-up (T2).AMT was assessed at T0 and T1.
|
29763431 |
2018 |
|
Depressive disorder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
NEIS, HADS and EORTC QLQ-C15-PAL were assessed at baseline (T0), 1 month later (post-treatment; T1), and at 1 month follow-up (T2).AMT was assessed at T0 and T1.
|
29763431 |
2018 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
The PAL project develops a conversational agent with a physical (robot) and virtual (avatar) embodiment to support diabetes self-management of children ubiquitously.
|
29548599 |
2018 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
The PAL project develops a conversational agent with a physical (robot) and virtual (avatar) embodiment to support diabetes self-management of children ubiquitously.
|
29548599 |
2018 |
|
Dysplastic Nevus
|
0.010 |
Biomarker
|
disease |
BEFREE |
MoAb PAL-M1 reacted with all 15 melanoma metastases (MM), with 14 of 19 primary cutaneous melanomas (PCM), 9 of 35 dysplastic nevi (DN), and 2 of 26 NN.
|
3891875 |
1985 |
|
Erythema Chronicum Migrans
|
0.010 |
Biomarker
|
disease |
BEFREE |
The DNA profile of NCH-1 was most similar to those of strain 297 (human cerebrospinal fluid isolate, Connecticut) and strain PAL (human erythema migrans isolate, New York) and most dissimilar from those of strain P/Gau (human erythema migrans isolate, Germany) and strain IPF (Ixodes persulcatus tick isolate, Japan).
|
1551988 |
1992 |
|
Fatigue
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Analysis of the QLQ-C15-PAL and BN20 scales revealed significant deterioration in patients treated with WBRT and SRT in physical function (p < 0.001 and p = 0.007), fatigue (p < 0.001 and p = 0.036), nausea (p = 0.003 and p = 0.002), appetite loss (p < 0.001 and p = 0.025), drowsiness (p < 0.001 and p = 0.011), hair loss (p = 0.019 and p = 0.023) and itchy skin (p = 0.030 and p = 0.018).
|
31418046 |
2020 |
|
Feeling despair
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Outcome measures were ego-integrity and despair (NEIS), psychological distress, anxiety and depression (HADS), quality of life (EORTC QLQ-C15-PAL), and specificity of the autobiographical memory (AMT).
|
29763431 |
2018 |
|
Gingivitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
PAL-V achieved by regenerative therapy in infrabony defects is as stable over 5 years as periodontally reduced but gingivally healthy or gingivitis sites.
|
30972774 |
2019 |
|
Glossitis, Benign Migratory
|
0.010 |
Biomarker
|
disease |
BEFREE |
The DNA profile of NCH-1 was most similar to those of strain 297 (human cerebrospinal fluid isolate, Connecticut) and strain PAL (human erythema migrans isolate, New York) and most dissimilar from those of strain P/Gau (human erythema migrans isolate, Germany) and strain IPF (Ixodes persulcatus tick isolate, Japan).
|
1551988 |
1992 |
|
Heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
(Palliative Care in Heart Failure [PAL-HF]; NCT01589601).
|
28705314 |
2017 |
|
Hemangioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
By contrast, blood vessel endothelium and hemangiomas were strongly positive for PAL-E and CD34 but were mostly negative for CD9 and podoplanin.
|
14559986 |
2003 |